Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telipro AM
- Development stage
- Phase 4
- Lead developer
- Docventures
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Telipro AM is a fixed-dose combination antihypertensive medication developed and marketed by Docventures Pharmaceuticals. It contains two active small molecule ingredients: telmisartan (40 mg) and amlodipine (5 mg). Telmisartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Amlodipine is a dihydropyridine calcium channel blocker (CCB) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation. Together, these mechanisms work synergistically to lower blood pressure by relaxing blood vessels and reducing peripheral resistance, making it easier for the heart to pump blood around the body.
- Brand names
- Telipro AM
- Other names
- telmisartan + amlodipine
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on Telipro AM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telipro AM.